London: A UK-based biotech company has declared positive ‘breakthrough’ results from a clinical trial of a protein-based treatment for Covid-19, which ‘greatly’ reduced patients requiring intensive care.
Synairgen said its SNG001 formulation uses a protein called interferon beta, which the body produces when it gets a viral infection, and is inhaled directly into the lungs of patients with coronavirus, using a nebuliser, in the hope that it will stimulate an immune response.
“This assessment of SNG001 in Covid-19 patients could signal a major breakthrough in the treatment of hospitalised Covid-19 patients”, said Richard Marsden, CEO of Synairgen, a respiratory drug discovery and development company which originated from research at the University of Southampton.
“We are all delighted with the trial results announced today, which showed that SNG001 greatly reduced the number of hospitalised COVID-19 patients who progressed from requiring oxygen’ to requiring ventilation’. It also showed that patients who received SNG001 were at least twice as likely to recover to the point where their everyday activities were not compromised through having been infected by SARS-CoV-2,” he added.